GlyCLICK® ADC

Site-specific conjugation of IgG with MMAE or PNU

Available Products

GlyCLICK is a three-step conjugation technology for site-specific and quantitative conjugation of IgG from several species and subclasses.

GlyCLICK ADC is available for site-specific labeling of 2 mg IgG with MMAE (Monomethyl auristatin E) or PNU (PNU anthracycline payload), and is suitable for the development of antibody-drug conjugates (ADCs).

MMAE is a potent cytotoxin that inhibits microtubule assembly and tubulin-dependent GTP hydrolysis, causing cell cycle arrest and apoptosis.
PNU is an anthracycline based DNA-alkylating toxin causing apoptosis with significantly higher potency that tubulin-targeting payloads.

Why GlyCLICK® ADC?

  • Site-specific payload-conjugation to IgG with a consistent drug-antibody ratio (DAR) of 2
  • Unique linker payloads with a two-step enzymatic release mechanism
  • Generates a site-specific ADC without antibody engineering
  • Preserved immunoreactivity with greater control of cytotoxicity

Available Products

  • GlyCLICK® ADC MMAE 2 mg

    Site-specific conjugation of 2 mg IgG with MMAE

    L1-T02-200

    2,369.00

    • GlyCLICK® ADC PNU 2 mg

      Site-specific conjugation of 2 mg IgG with PNU

      L1-T01-200

      2,690.00

      For information on how to order, visit Place an Order or contact us directly at order@genovis.com.

      Product Information

      Unit Defintion

      GlyCLICK ADC contains sufficient material for labeling of 2 mg IgG. For larger amounts or evaluation of the technology, please contact us.

      Contents

      Components in GlyCLICK ADC:

      • GlycINATOR Immobilized
      • UDP-GalNAz
      • GalT(Y289L)
      • sDIBO (MMAE or PNU)
      • All buffers needed
      • Concentration and desalting columns

      Storage

      The components of GlyCLICK ADC should be stored at different temperatures upon arrival.

      Resources

      Applications